Additional Information

Description

Descovy® is a fixed-dose combination tablet containing emtricitabine (200 mg) and tenofovir alafenamide (25 mg), both of which are nucleotide reverse transcriptase inhibitors (NRTIs). This medication is used for the treatment of HIV-1 infection in combination with other antiretroviral agents. It is also approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in high-risk individuals.

Each film-coated tablet is taken once daily with or without food. The drug is absorbed rapidly and metabolized into its active metabolites. Emtricitabine and tenofovir alafenamide work together to inhibit viral replication. Emtricitabine blocks the reverse transcription process, while tenofovir alafenamide interferes with viral DNA synthesis.

Common side effects of Descovy® include headache, nausea, diarrhea, and fatigue. Serious adverse effects may include kidney problems, liver dysfunction, and bone density loss. Regular monitoring of renal and hepatic function is recommended during treatment.